More on 688192
News
- Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
- Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
- Dizal's ZEGFROVY beats chemotherapy in lung cancer trial
- Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
- Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutate
- Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026
- Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
- Dizal reports positive phase 3 results for lung cancer drug ZEGFROVY
- Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Ca
- Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
Entities mentioned with 688192
- FDA | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
